CN113249309A - 一种使脂肪自动凋亡的技术 - Google Patents
一种使脂肪自动凋亡的技术 Download PDFInfo
- Publication number
- CN113249309A CN113249309A CN202110537374.7A CN202110537374A CN113249309A CN 113249309 A CN113249309 A CN 113249309A CN 202110537374 A CN202110537374 A CN 202110537374A CN 113249309 A CN113249309 A CN 113249309A
- Authority
- CN
- China
- Prior art keywords
- fat
- solution
- culture medium
- adipocytes
- technique
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000006907 apoptotic process Effects 0.000 title claims abstract description 11
- 238000005516 engineering process Methods 0.000 title abstract description 10
- 210000001789 adipocyte Anatomy 0.000 claims abstract description 37
- 239000001963 growth medium Substances 0.000 claims abstract description 25
- 239000000243 solution Substances 0.000 claims abstract description 20
- 230000003115 biocidal effect Effects 0.000 claims abstract description 17
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 14
- 239000003855 balanced salt solution Substances 0.000 claims abstract description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 12
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 7
- 229960001031 glucose Drugs 0.000 claims abstract description 7
- 239000012595 freezing medium Substances 0.000 claims abstract description 6
- 239000007787 solid Substances 0.000 claims abstract description 6
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229910001424 calcium ion Inorganic materials 0.000 claims abstract description 5
- 229910001425 magnesium ion Inorganic materials 0.000 claims abstract description 5
- 241000894006 Bacteria Species 0.000 claims abstract description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 4
- 238000007664 blowing Methods 0.000 claims abstract description 4
- 239000011575 calcium Substances 0.000 claims abstract description 4
- 238000012258 culturing Methods 0.000 claims abstract description 4
- 239000008367 deionised water Substances 0.000 claims abstract description 4
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 4
- 238000007865 diluting Methods 0.000 claims abstract description 4
- 229920000669 heparin Polymers 0.000 claims abstract description 4
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 claims abstract description 4
- 229960001008 heparin sodium Drugs 0.000 claims abstract description 4
- 229960003080 taurine Drugs 0.000 claims abstract description 4
- 229940088594 vitamin Drugs 0.000 claims abstract description 4
- 229930003231 vitamin Natural products 0.000 claims abstract description 4
- 235000013343 vitamin Nutrition 0.000 claims abstract description 4
- 239000011782 vitamin Substances 0.000 claims abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 12
- 235000006708 antioxidants Nutrition 0.000 claims description 11
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 8
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 6
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 6
- 229960005322 streptomycin Drugs 0.000 claims description 4
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims description 3
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 3
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 claims description 3
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 3
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 3
- 229930182555 Penicillin Natural products 0.000 claims description 3
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 claims description 3
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 claims description 3
- 229930003427 Vitamin E Natural products 0.000 claims description 3
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims description 3
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 3
- 239000001110 calcium chloride Substances 0.000 claims description 3
- 235000011148 calcium chloride Nutrition 0.000 claims description 3
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 3
- 229960003531 phenolsulfonphthalein Drugs 0.000 claims description 3
- 235000002949 phytic acid Nutrition 0.000 claims description 3
- 229940068041 phytic acid Drugs 0.000 claims description 3
- 239000000467 phytic acid Substances 0.000 claims description 3
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 3
- 229960004172 pyridoxine hydrochloride Drugs 0.000 claims description 3
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 claims description 3
- 239000011764 pyridoxine hydrochloride Substances 0.000 claims description 3
- 229960002477 riboflavin Drugs 0.000 claims description 3
- 235000019192 riboflavin Nutrition 0.000 claims description 3
- 239000002151 riboflavin Substances 0.000 claims description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 3
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 3
- 229960000344 thiamine hydrochloride Drugs 0.000 claims description 3
- 235000019190 thiamine hydrochloride Nutrition 0.000 claims description 3
- 239000011747 thiamine hydrochloride Substances 0.000 claims description 3
- 150000003626 triacylglycerols Chemical class 0.000 claims description 3
- 235000019165 vitamin E Nutrition 0.000 claims description 3
- 229940046009 vitamin E Drugs 0.000 claims description 3
- 239000011709 vitamin E Substances 0.000 claims description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 2
- 229940049954 penicillin Drugs 0.000 claims description 2
- 239000002609 medium Substances 0.000 claims 1
- 239000011550 stock solution Substances 0.000 abstract description 6
- 230000032683 aging Effects 0.000 abstract description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 5
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 239000003925 fat Substances 0.000 description 23
- 241000282414 Homo sapiens Species 0.000 description 10
- 238000001816 cooling Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 238000007710 freezing Methods 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004324 lymphatic system Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000007493 shaping process Methods 0.000 description 2
- 241000304886 Bacilli Species 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0653—Adipocytes; Adipose tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
- C12N2500/33—Amino acids other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/34—Sugars
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/90—Polysaccharides
- C12N2501/91—Heparin
Abstract
本发明涉及脂肪领域,且公开了一种使脂肪自动凋亡的技术,其包括脂肪细胞和用于培养脂肪细胞的培养液;所述培养液包括平衡盐溶液、培养基、冻存液和用于防止脂肪细胞感染革兰氏菌的原核抗生素,所述平衡盐溶液包括不含有钙和镁离子的D‑Hank's,所述培养基包括去离子水、抗氧化剂、D‑葡萄糖、维生素、牛磺酸和肝素钠,所述冻存液中包含10%的DMSO和至少10%的FBS;将所述脂肪细胞放置在器皿上,然后将冻存液滴入器皿并稀释吹匀,2min后加入平衡盐溶液及培养基,10min后加入原核抗生素,冻存液、平衡液溶液、培养基与原核抗生素的比例为1:2:0.5:0.1。本发明通过将脂肪细胞放置在恒温4℃的环境下,使脂肪细胞中的甘油三酯会在24H内转变成固体,促使脂肪细胞提早老化凋亡。
Description
技术领域
本发明属于脂肪领域,具体为一种使脂肪自动凋亡的技术。
背景技术
脂质是油、脂肪、类脂的总称。食物中的油性物质主要是油和脂肪,一般把常温下是液体的称作油,而把常温下是固体的称作脂肪。脂肪由C、H、O三种元素组成。脂肪是由甘油和脂肪酸组成的甘油三酯,其中甘油的分子比较简单,而脂肪酸的种类和长短却不相同。
目前,肥胖已经是人类中常见的问题,肥胖主要是身体明显超重与脂肪层过厚,是体内脂肪,尤其是甘油三酯积聚过多而导致的一种状态,而目前没有很好的能够消除脂肪中甘油三酯的技术,因此设计一种使脂肪自动凋亡的技术来解决这种问题很有必要。
发明内容
本发明的目的在于:为解决上述背景技术中提出的问题,本发明提供了一种使脂肪自动凋亡的技术。
为实现上述目的,本发明提供如下技术方案:一种使脂肪自动凋亡的技术,包括脂肪细胞和用于培养脂肪细胞的培养液;所述培养液包括平衡盐溶液、培养基、冻存液和用于防止脂肪细胞感染革兰氏菌的原核抗生素,所述平衡盐溶液包括不含有钙和镁离子的D-Hank's,所述培养基包括去离子水、抗氧化剂、D-葡萄糖、维生素、牛磺酸和肝素钠,所述冻存液中包含10%的DMSO和至少10%的FBS;将所述脂肪细胞放置在器皿上,然后将冻存液滴入器皿并稀释吹匀,2min后加入平衡盐溶液及培养基,10min后加入原核抗生素,冻存液、平衡液溶液、培养基与原核抗生素的比例为1:2:0.5:0.1,之后将脂肪细胞放置在恒温4℃的环境下,以用于将脂肪细胞内的三酸甘油酯凝固呈固体。
进一步的,所述D-Hank's内包含有0.001%酚红、1%D-葡萄糖、0.08%KCl、0.1%NaHCO3、0.006%CaCl2和0.005%KH2PO4。
进一步的,所述培养基包括吡哆醇盐酸盐、核黄素、盐酸硫氨。
进一步的,所述培养基内包含有1.5%的抗氧化剂,所述抗氧化剂包括维生素E、抗坏血酸棕榈酸酯、植酸、BHT等含有抗氧化性的自由基。
进一步的,所述原核抗生素包括青霉素。
进一步的,所述原核抗生素包括链霉素。
与现有技术相比,本发明的有益效果是:
本发明通过将脂肪细胞放置在器皿上,然后将冻存液滴入器皿并稀释吹匀,2min后加入平衡盐溶液及培养基,10min后加入原核抗生素,冻存液、平衡液溶液、培养基与原核抗生素的比例为1:2:0.5:0.1,这样脂肪细胞即能够复苏,并由培养基提供的能量继续生长,之后将脂肪细胞放置在恒温4℃的环境下,此时脂肪细胞中的甘油三酯会在24H内转变成固体,达到促使脂肪细胞提早老化凋亡的效果,这一技术可以应用在人体脂肪,通过将对人体局部皮肤进行4℃的冷却,冻结冷却脂肪后,可以促使脂肪提早老化,凋亡的脂肪细胞经由人体的淋巴系统代谢排出,通过长时间、精准冷却局部皮肤冷却,人体会在自然代谢过程中将逐渐减少的脂肪层的厚度,达到塑身瘦身的效果。
具体实施方式
下面将对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例;基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
本具体实施方式提供的一种使脂肪自动凋亡的技术,包括脂肪细胞和用于培养脂肪细胞的培养液;培养液包括平衡盐溶液、培养基、冻存液和用于防止脂肪细胞感染革兰氏菌的原核抗生素,平衡盐溶液包括不含有钙和镁离子的D-Hank's,培养基包括去离子水、抗氧化剂、D-葡萄糖、维生素、牛磺酸和肝素钠,冻存液中包含10%的DMSO和至少10%的FBS;将脂肪细胞放置在器皿上,然后将冻存液滴入器皿并稀释吹匀,2min后加入平衡盐溶液及培养基,10min后加入原核抗生素,冻存液、平衡液溶液、培养基与原核抗生素的比例为1:2:0.5:0.1,这样脂肪细胞即能够复苏,并由培养基提供的能量继续生长,之后将脂肪细胞放置在恒温4℃的环境下,此时脂肪细胞中的甘油三酯会在24H内转变成固体,达到促使脂肪细胞提早老化凋亡的效果,这一技术可以应用在人体脂肪,通过将对人体局部皮肤进行4℃的冷却,冻结冷却脂肪后,可以促使脂肪提早老化,凋亡的脂肪细胞经由人体的淋巴系统代谢排出,通过长时间、精准冷却局部皮肤冷却,人体会在自然代谢过程中将逐渐减少的脂肪层的厚度,达到塑身瘦身的效果。
具体的,D-Hank's内包含有0.001%酚红、1%D-葡萄糖、0.08%KCl、0.1%NaHCO3、0.006%CaCl2和0.005%KH2PO4,其成分中相比Hank's液缺少了钙离子与镁离子,从而不会影响脂肪中胰蛋白酶的活性。
具体的,培养基包括吡哆醇盐酸盐、核黄素、盐酸硫氨,以对复苏的脂肪细胞提供营养。
具体的,培养基内包含有1.5%的抗氧化剂,抗氧化剂包括维生素E、抗坏血酸棕榈酸酯、植酸、BHT等含有抗氧化性的自由基,抗氧化剂能够明显减少脂肪细胞的死亡率,并提高其生长的速度。
具体的,原核抗生素包括青霉素,青霉素能够针对革兰氏阳性菌发挥抗菌的作用。
同时,原核抗生素包括链霉素,链霉素则能够对许多革兰阴性杆菌起到抗菌的作用。
需要说明的是,在本文中,诸如第一和第二等之类的关系术语仅仅用来将一个实体或者操作与另一个实体或操作区分开来,而不一定要求或者暗示这些实体或操作之间存在任何这种实际的关系或者顺序。而且,术语“包括”、“包含”或者其任何其他变体意在涵盖非排他性的包含,从而使得包括一系列要素的过程、方法、物品或者设备不仅包括那些要素,而且还包括没有明确列出的其他要素,或者是还包括为这种过程、方法、物品或者设备所固有的要素。
尽管已经示出和描述了本发明的实施例,对于本领域的普通技术人员而言,可以理解在不脱离本发明的原理和精神的情况下可以对这些实施例进行多种变化、修改、替换和变型,本发明的范围由所附权利要求及其等同物限定。
Claims (6)
1.一种使脂肪自动凋亡的技术,其特征在于,包括脂肪细胞和用于培养脂肪细胞的培养液;
所述培养液包括平衡盐溶液、培养基、冻存液和用于防止脂肪细胞感染革兰氏菌的原核抗生素,所述平衡盐溶液包括不含有钙和镁离子的D-Hank's,所述培养基包括去离子水、抗氧化剂、D-葡萄糖、维生素、牛磺酸和肝素钠,所述冻存液中包含10%的DMSO和至少10%的FBS;
将所述脂肪细胞放置在器皿上,然后将冻存液滴入器皿并稀释吹匀,2min后加入平衡盐溶液及培养基,10min后加入原核抗生素,冻存液、平衡液溶液、培养基与原核抗生素的比例为1:2:0.5:0.1,之后将脂肪细胞放置在恒温4℃的环境下,以用于将脂肪细胞内的三酸甘油酯凝固呈固体。
2.根据权利要求1所述的一种使脂肪自动凋亡的技术,其特征在于,所述D-Hank's内包含有0.001%酚红、1%D-葡萄糖、0.08%KCl、0.1%NaHCO3、0.006%CaCl2和0.005%KH2PO4。
3.根据权利要求1所述的一种使脂肪自动凋亡的技术,其特征在于,所述培养基包括吡哆醇盐酸盐、核黄素、盐酸硫氨。
4.根据权利要求1所述的一种使脂肪自动凋亡的技术,其特征在于,所述培养基内包含有1.5%的抗氧化剂,所述抗氧化剂包括维生素E、抗坏血酸棕榈酸酯、植酸、BHT等含有抗氧化性的自由基。
5.根据权利要求1所述的一种使脂肪自动凋亡的技术,其特征在于,所述原核抗生素包括青霉素。
6.根据权利要求1所述的一种使脂肪自动凋亡的技术,其特征在于,所述原核抗生素包括链霉素。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110537374.7A CN113249309A (zh) | 2021-05-18 | 2021-05-18 | 一种使脂肪自动凋亡的技术 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110537374.7A CN113249309A (zh) | 2021-05-18 | 2021-05-18 | 一种使脂肪自动凋亡的技术 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113249309A true CN113249309A (zh) | 2021-08-13 |
Family
ID=77183358
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110537374.7A Pending CN113249309A (zh) | 2021-05-18 | 2021-05-18 | 一种使脂肪自动凋亡的技术 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113249309A (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030220674A1 (en) * | 2002-03-15 | 2003-11-27 | Anderson Richard Rox | Methods and devices for selective disruption of fatty tissue by controlled cooling |
CN103060264A (zh) * | 2012-12-20 | 2013-04-24 | 上海市第十人民医院 | 一种干细胞培养基及其应用和干细胞培养方法 |
CN105165804A (zh) * | 2015-10-28 | 2015-12-23 | 广州赛莱拉干细胞科技股份有限公司 | 一种脂肪间充质干细胞的冻存保护液及冻存方法 |
CN107114355A (zh) * | 2016-08-01 | 2017-09-01 | 北京世纪劲得生物技术有限公司 | 一种脂肪细胞保护液及其制备方法 |
CN112753694A (zh) * | 2020-12-25 | 2021-05-07 | 江苏艾尔康生物医药科技有限公司 | 一种细胞冻存液和用于间充质干细胞的冷冻方法及其应用 |
-
2021
- 2021-05-18 CN CN202110537374.7A patent/CN113249309A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030220674A1 (en) * | 2002-03-15 | 2003-11-27 | Anderson Richard Rox | Methods and devices for selective disruption of fatty tissue by controlled cooling |
CN103060264A (zh) * | 2012-12-20 | 2013-04-24 | 上海市第十人民医院 | 一种干细胞培养基及其应用和干细胞培养方法 |
CN105165804A (zh) * | 2015-10-28 | 2015-12-23 | 广州赛莱拉干细胞科技股份有限公司 | 一种脂肪间充质干细胞的冻存保护液及冻存方法 |
CN107114355A (zh) * | 2016-08-01 | 2017-09-01 | 北京世纪劲得生物技术有限公司 | 一种脂肪细胞保护液及其制备方法 |
CN112753694A (zh) * | 2020-12-25 | 2021-05-07 | 江苏艾尔康生物医药科技有限公司 | 一种细胞冻存液和用于间充质干细胞的冷冻方法及其应用 |
Non-Patent Citations (2)
Title |
---|
刘静等: "Ghrelin对3T3-L1前脂肪细胞增殖和凋亡作用的研究", 《临床儿科杂志》 * |
银平章主编: "《临床病理学实验技术》", 31 July 1997 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103766944B (zh) | 一种通电快速腌制肉类的方法 | |
CN108578266B (zh) | 一种抗氧化组合物及其在面膜液中的应用 | |
CN105638848A (zh) | 一种畜禽肉冻结及解冻方法 | |
CN104996539A (zh) | 一种鱿鱼保水剂及其制备方法、应用 | |
CN113249309A (zh) | 一种使脂肪自动凋亡的技术 | |
CN114752637B (zh) | 一种甘油二酯食用油及其制备方法及即食米饭保鲜剂 | |
CN103271217A (zh) | 一种罗非鱼鱼皮及鱼鳞提取鱼胶原蛋白粉的生产方法 | |
CN102232562B (zh) | 一种牛胴体的排酸工艺 | |
CN103875795B (zh) | 一种冷冻贻贝生物抑菌剂及制备方法和应用 | |
ES553739A0 (es) | Un metodo para conservar bacterias productoras de acido | |
Lan et al. | Relevance of cathepsins activity and texture in slightly acidic electrolyzed water-slurry iced mackerel (Pneumatophorus japonicus) | |
GB1405512A (en) | Milk product and process | |
CN105125427A (zh) | 一种皮肤保湿修复凝胶及其制备方法 | |
Arkhipov et al. | Change of qualitative characteristics of deep-chilled rainbow trout fillet with a given amount of ice water (no more than 40%) during its long-term storage | |
CN108567674A (zh) | 一种海参面膜及其制备方法 | |
CN103214592A (zh) | 一种西藏灵菇多糖的制备方法 | |
CN107997985A (zh) | 鹿皮多糖在制备保湿化妆品中的应用 | |
CN103168827A (zh) | 胶原蛋白与壳聚糖通过美拉德反应制备保鲜涂膜的方法 | |
Suthanthangjai et al. | Bioconversion of Pinot noir anthocyanins into bioactive phenolic compounds by lactic acid bacteria | |
CN208891637U (zh) | 一种生鲜食品冰寒超长保鲜灭菌装置 | |
JPS5726567A (en) | Freeze preservation of raw laver leaf | |
CN112568385A (zh) | 一种酶法制备干海参的方法 | |
IE36487B1 (en) | Method of preserving fresh meat | |
CN116590087A (zh) | 一种海参花油脂提取制备工艺方法及应用 | |
US4278698A (en) | Method of cooling cooked products by interval showering |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210813 |
|
RJ01 | Rejection of invention patent application after publication |